Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

41. A Controlled Clinical Trial on the Effects of Exercise on Cognition and Mobility in Adults With Multiple Sclerosis. Full Text available with Trip Pro

A Controlled Clinical Trial on the Effects of Exercise on Cognition and Mobility in Adults With Multiple Sclerosis. The aim of the study was to investigate the effects of a 6-mo exercise program on cognition and mobility in participants with multiple sclerosis.This is a prospective, single-blind, controlled clinical trial.A community rehabilitation program within a large metropolitan health service.Twenty-eight patients with multiple sclerosis were referred for outpatient (...) did not have significant changes in cognition scores after 6 mos of follow-up and had a worse performance in mobility tests.Six months of exercise provided benefits to cognition and mobility in adults with multiple sclerosis. This trial was registered prospectively with the Brazilian Clinical Trials Register, ID: RBR-9gh4km (http://www.ensaiosclinicos.gov.br/rg/?q=RBR-9gh4km).Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

42. Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112.

Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112. Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis - Repository of AIHTA GmbH English | Browse - - - Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis Fuchs, E. (2019): Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 659kB (...) Abstract Introduction: Worldwide, more than 2.5 million people suffer from Multiple Sclerosis (MS), which is a progressive degenerating disease of the central nervous system (CNS). At present, there is no definitive cure. Thus, available pharmacological therapies aim to reduce the disease activity by either suppressing or modulating the immune system. The humanised monoclonal antibody natalizumab (Tysabri™) was approved for the treatment of relapsing-remitting MS by the FDA and the EMA in 2006

2019 Austrian Institute of Health Technology Assessment

43. Ocrelizumab (Ocrevus) - relapsing forms of multiple sclerosis

Ocrelizumab (Ocrevus) - relapsing forms of multiple sclerosis 1 Published 10 December 2018 1 SMC2121 ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®) Roche Products Ltd Resubmission 9 November 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission ocrelizumab (Ocrevus® (...) ) is accepted for restricted use within NHSScotland. Indication under review: The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: Treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for alemtuzumab. Two phase III studies identified superiority of ocrelizumab when compared

2018 Scottish Medicines Consortium

44. Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria Full Text available with Trip Pro

Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by adaptive and innate immune system dysregulation. Recent work has revealed moderate alteration of gut microbial communities in subjects with MS and in experimental, induced models. However, a mechanistic understanding linking the observed changes in the microbiota and the presence of the disease

2018 mSystems

45. Fampridine (Fampyra) - multiple sclerosis

Fampridine (Fampyra) - multiple sclerosis 1 Published 12 November 2018 1 SMC2107 fampridine 10mg prolonged-release tablet (Fampyra®) Biogen Idec Ltd Resubmission 05 October 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission fampridine (Fampyra ® ) is not recommended for use within (...) NHSScotland. Indication under review: For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7). In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiple sclerosis and walking impairment. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2

2018 Scottish Medicines Consortium

46. ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis Full Text available with Trip Pro

ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis To evaluate the effect of the Assistive Device Selection, Training and Education Program (ADSTEP) on falls and walking and sitting activity in people with multiple sclerosis (PwMS).Randomized controlled trial.Veterans affairs medical center.PwMS (N=40) using a walking aid at baseline who had fallen in the previous year.Participants were randomly assigned to ADSTEP or control. ADSTEP had 6 (...) Technologies, Multiple Sclerosis Walking Scale-12, Activities-Specific Balance Confidence Scale, and Multiple Sclerosis Impact Scale-29. Effect on these outcomes was estimated by a 2-by-2 repeated measures general linear model.Fewer ADSTEP than control participants fell (χ2=3.96, P<.05. number needed to treat =3.3). Time spent sitting changed significantly differently with ADSTEP than with control from baseline to intervention completion (F=11.16, P=.002. ADSTEP: reduced 87.00±194.89min/d; control

2018 EvidenceUpdates

47. Information provision for people with multiple sclerosis. Full Text available with Trip Pro

Information provision for people with multiple sclerosis. People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. These include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies, and non-pharmacological interventions, among others. While people with MS demand adequate information to be able to actively participate in medical decision making and to self manage their disease, it has (...) to promote informed choice and improve patient-relevant outcomes, Further objectives were to evaluate the components and the developmental processes of the complex interventions used, to highlight the quantity and the certainty of the research evidence available, and to set an agenda for future research.For this update, we searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register, which contains trials from CENTRAL (the Cochrane Library 2017

2018 Cochrane

48. Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study (Abstract)

Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study To investigate discriminative ability and clinical utility of the Timed Up and Go under single- and dual-task conditions between fallers and non-fallers in multiple sclerosis (MS).Prospective cohort study.Neurology service in a tertiary hospital.Participants were 101 people with MS and Expanded Disability Status Scale score of 3-6.5 (...) -Cognitive in distinguishing fallers (person with ⩾1 fall) from non-fallers are 0.60 and 0.57, respectively, and in distinguishing multiple fallers (⩾2 falls) the values are 0.46 and 0.43. A Timed Up and Go score of ⩾9 seconds has a sensitivity of 0.82 and a specificity of 0.34 to identify fallers and a sensitivity of 0.79 and a specificity of 0.27 to identify multiple fallers. A Timed Up and Go-Cognitive score of ⩾11 seconds has a sensitivity of 0.77 and a specificity of 0.30 to identify fallers

2018 EvidenceUpdates

49. Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management Full Text available with Trip Pro

Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management This study evaluated the relationship between physiological and perceived fall risk in people with multiple sclerosis (MS).Secondary analysis of data from prospective cohort studies undertaken in Australia, the United Kingdom, and the United States.Community.Ambulatory people with MS (N=416) (age 51.5±12.0 years; 73% female; 62% relapsing-remitting MS; 13.7

2018 EvidenceUpdates

50. Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis Full Text available with Trip Pro

Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis To assess the diagnostic and clinical utility of the 2-item Generalized Anxiety Disorder Scale (GAD-2) for screening anxiety symptoms in individuals with multiple sclerosis (MS).Cross-sectional.University-affiliated MS neurology and rehabilitation center.The sample comprised adults (N=99) (ages 19-72; mean ± SD=46.2±13.0; 75% women) with a physician-confirmed MS diagnosis who were

2018 EvidenceUpdates

51. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. (Abstract)

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population.In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body (...) ; relative difference, 82%; P<0.001). The key secondary end point of the annualized rate of new or newly enlarged lesions on T2-weighted magnetic resonance imaging (MRI) was 4.39 with fingolimod and 9.27 with interferon beta-1a (absolute difference, 4.88 lesions; relative difference, 53%; P<0.001). Adverse events, excluding relapses of multiple sclerosis, occurred in 88.8% of patients who received fingolimod and 95.3% of those who received interferon beta-1a. Serious adverse events occurred in 18

2018 NEJM Controlled trial quality: predicted high

52. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. Full Text available with Trip Pro

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis.We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg (...) less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression.In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT

2018 NEJM Controlled trial quality: predicted high

53. Tumefactive multiple sclerosis masquerade as a central nervous system tumor: a case report Full Text available with Trip Pro

Tumefactive multiple sclerosis masquerade as a central nervous system tumor: a case report Tumefactive multiple sclerosis is a demyelinating disorder that appears tumor-like on MRI. To most physicians, diagnosing tumefactive MS by applying clinical, radiological, or laboratory examination like Cerebrospinal fluid (CSF) analysis, can be challenging and ultimately biopsy is necessary to confirm the diagnosis.This paper reports a case of a 37-year-old woman who presented with progressive headache

2018 Electronic physician

54. Multiple sclerosis

Multiple sclerosis Top results for multiple sclerosis - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for multiple sclerosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

55. Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial (Abstract)

Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial To examine moderators of treatment effects in a randomized controlled trial comparing a telehealth self-management intervention with a telehealth multiple sclerosis (MS) education intervention for fatigue, pain, and mood in adults with MS.Secondary analysis of a single-blind randomized controlled trial.Community.Adults with MS

2018 EvidenceUpdates

56. Pharmacological treatment for memory disorder in multiple sclerosis

Pharmacological treatment for memory disorder in multiple sclerosis Pharmacological treatment for memory disorder in multiple sclerosis - He, D - 2013 | Cochrane Library Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in . Trusted evidence. Informed decisions. Better health (...) Collections Pharmacological treatment for memory disorder in multiple sclerosis Cochrane Systematic Review - Intervention Version published: 17 December 2013 New search Collapse all Expand all Abstract available in Background This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10). Multiple sclerosis (MS) is a chronic immune‐mediated, inflammatory, demyelinating, neurodegenerative disorder

2018 European Academy of Neurology

57. Ocrelizumab for treating relapsing?remitting multiple sclerosis

Ocrelizumab for treating relapsing?remitting multiple sclerosis Ocrelizumab for treating Ocrelizumab for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 25 July 2018 nice.org.uk/guidance/ta533 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 Information about

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

58. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study Full Text available with Trip Pro

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS).Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary endpoint of cumulative number of new

2018 EvidenceUpdates Controlled trial quality: uncertain

59. Multiple sclerosis

Multiple sclerosis Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

60. Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial (Abstract)

Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial To evaluate the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis.It was a three-arm parallel randomized clinical trial study.Outpatient clinic.Patients with multiple sclerosis.Participants in the intervention groups completed an eight-week program consisting (...) obtained for the sexual function of mindfulness group were 19.5 ± 6.4, 26.9 ± 4.8, and 25.6 ± 4.5, respectively. Moreover, mean scores obtained for pelvic floor muscle exercise along with mindfulness were 19.6 ± 5.9, 25.3 ± 5.4, and 25 ± 4.8, respectively. There was no significant difference in their effects on sexual function ( P > 0.05).Mindfulness and pelvic floor muscle exercise do not have any significant impact upon sexual dysfunction of people with multiple sclerosis.

2018 EvidenceUpdates